Log in

Affimed Stock Price, News & Analysis (NASDAQ:AFMD)

$2.88
-0.18 (-5.88 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
$2.84
Now: $2.88
$3.07
50-Day Range
$2.64
MA: $3.02
$3.71
52-Week Range
$2.52
Now: $2.88
$5.08
Volume391,565 shs
Average Volume548,489 shs
Market Capitalization$179.68 million
P/E RatioN/A
Dividend YieldN/A
Beta2.85
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AFMD
CUSIPN/A
Phone49-62-2167-4360

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$28.03 million
Book Value$0.76 per share

Profitability

Net Income$-23,000,000.00

Miscellaneous

Employees8,406
Market Cap$179.68 million
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive AFMD News and Ratings via Email

Sign-up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter.


Affimed (NASDAQ:AFMD) Frequently Asked Questions

What is Affimed's stock symbol?

Affimed trades on the NASDAQ under the ticker symbol "AFMD."

How were Affimed's earnings last quarter?

Affimed NV (NASDAQ:AFMD) issued its earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, hitting analysts' consensus estimates of ($0.16). The biopharmaceutical company had revenue of $4.50 million for the quarter, compared to the consensus estimate of $6.46 million. Affimed had a negative net margin of 30.87% and a negative return on equity of 30.94%. View Affimed's Earnings History.

When is Affimed's next earnings date?

Affimed is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Affimed.

What price target have analysts set for AFMD?

3 brokers have issued 1-year price objectives for Affimed's shares. Their predictions range from $4.17 to $10.00. On average, they expect Affimed's share price to reach $7.39 in the next year. This suggests a possible upside of 156.6% from the stock's current price. View Analyst Price Targets for Affimed.

What is the consensus analysts' recommendation for Affimed?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Affimed.

Has Affimed been receiving favorable news coverage?

News headlines about AFMD stock have been trending somewhat negative on Saturday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Affimed earned a daily sentiment score of -1.5 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Affimed.

Are investors shorting Affimed?

Affimed saw a decrease in short interest during the month of September. As of September 30th, there was short interest totalling 5,580,000 shares, a decrease of 10.0% from the August 30th total of 6,200,000 shares. Based on an average trading volume of 580,400 shares, the short-interest ratio is currently 9.6 days. Currently, 11.0% of the company's stock are short sold. View Affimed's Current Options Chain.

Who are some of Affimed's key competitors?

What other stocks do shareholders of Affimed own?

Who are Affimed's key executives?

Affimed's management team includes the folowing people:
  • Dr. Adi Hoess, CEO, MD & Member of Management Board (Age 57)
  • Dr. Florian H. M. Fischer, MD, CFO & Member of Management Board (Age 51)
  • Dr. Wolfgang Fischer, MD, COO & Member of Management Board (Age 55)
  • Prof. Melvyn Little, Founder & Consultant
  • Dr. Martin Treder, Chief Scientific Officer (Age 49)

Who are Affimed's major shareholders?

Affimed's stock is owned by a number of of retail and institutional investors. Top institutional investors include Meeder Asset Management Inc. (0.03%).

Which institutional investors are buying Affimed stock?

AFMD stock was bought by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc..

How do I buy shares of Affimed?

Shares of AFMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Affimed's stock price today?

One share of AFMD stock can currently be purchased for approximately $2.88.

How big of a company is Affimed?

Affimed has a market capitalization of $179.68 million and generates $28.03 million in revenue each year. The biopharmaceutical company earns $-23,000,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis. Affimed employs 8,406 workers across the globe.View Additional Information About Affimed.

What is Affimed's official website?

The official website for Affimed is http://www.affimed.com/.

How can I contact Affimed?

Affimed's mailing address is IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The biopharmaceutical company can be reached via phone at 49-62-2167-4360 or via email at [email protected]


MarketBeat Community Rating for Affimed (NASDAQ AFMD)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  358 (Vote Outperform)
Underperform Votes:  249 (Vote Underperform)
Total Votes:  607
MarketBeat's community ratings are surveys of what our community members think about Affimed and other stocks. Vote "Outperform" if you believe AFMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AFMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel